Ultragenyx gene therapy data disappoints investors

Ultragenyx Pharmaceutical on Wednesday released the first data from patients taking the planned Phase 3 dose of gene therapy DTX401 for a condition called glycogen storage disorder 1a. Yet that dose appeared only as effective as a lower dose used in an earlier group of patients.